Caspofungin and Voriconazole as Primary and Salvage Therapy for Patients with Invasive Aspergillosis in Hematologic Malignany

RAY HACHEM, GILBERT EL HELOU, ALINE EL Z AKHEM, WILLIAM SHOMALI, YING JIANG, ANNEMARIE CHAFTARI and ISSAM RAAD

Author address: 

University of Texas MD Anderson Cancer Center, Houston, TX

Abstract: 

Background: Invasive aspergillosis ( IA) remains a life-threatening infection in severely immunocompromised hematological malignancy (HM) patients. We evaluated the efficacy and safety of Caspofungin and Voriconazole as well as its combination as primary and salvage therapy for patients with IA. Methods: Between January 2000 and Jan 2011, a total of 231 patients with HM were diagnosed with IA as proven or probable (according to EORTC/MSG criteria). For primary antifungal therapy, there were 36 patients received Caspo alone, 51 patients received vori alone, and 42 patients received the combination vori + caspo. For salvage therapy, there were 23 patients received caspo alone, 32 patients received vori alone, and 47 patients received vori + caspo. Clinical characteristics as well as response to salvage therapy and safety data were retrospectively obtained on all patients. Results: The three primary groups were comparable in terms of age, gender, neutropenia at onset, duration and persistence of neutropenia, steroid use, pulmonary involvement, and duration of ICU stay. However, among the caspo and the combination therapy group more patients had leukemia or GVHD compared to those treated with vori alone p
2012

abstract No: 

226

Full conference title: 

ID Week 2012
    • IDWeek 2012